Shares of Surface Oncology Inc (NASDAQ:SURF) have received an average broker rating score of 1.00 (Strong Buy) from the two analysts that cover the company, Zacks Investment Research reports. Two equities research analysts have rated the stock with a strong buy recommendation.
Brokers have set a one year consensus price target of $ 26.00 for the company, according to Zacks. Zacks has also assigned Surface Oncology an industry rank of 167 out of 255 based on the ratings given to its competitors.
A number of research firms recently issued reports on SURF. Goldman Sachs Group began coverage on Surface Oncology in a report on Monday, May 14th. They set a “neutral” rating and a $ 17.00 price objective for the company. Cowen began coverage on Surface Oncology in a report on Monday, May 14th. They set an “outperform” rating for the company. Finally, Evercore ISI began coverage on Surface Oncology in a report on Monday, May 14th. They set an “outperform” rating and a $ 26.00 price objective for the company.
Shares of Surface Oncology traded up $ 0.14, reaching $ 17.01, during mid-day trading on Friday, according to MarketBeat. 353,572 shares of the company’s stock were exchanged, compared to its average volume of 342,918. Surface Oncology has a twelve month low of $ 12.08 and a twelve month high of $ 18.18.
Surface Oncology (NASDAQ:SURF) last posted its quarterly earnings data on Tuesday, May 29th. The company reported $ 1.05 earnings per share (EPS) for the quarter. The firm had revenue of $ 45.50 million for the quarter. research analysts anticipate that Surface Oncology will post -2.67 earnings per share for the current fiscal year.
In related news, Director David S. Grayzel purchased 100,000 shares of the firm’s stock in a transaction on Monday, April 23rd. The stock was purchased at an average cost of $ 15.00 per share, for a total transaction of $ 1,500,000.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Lilly Ventures Fund I. Llc purchased 266,000 shares of the firm’s stock in a transaction on Monday, April 23rd. The stock was bought at an average price of $ 15.00 per share, with a total value of $ 3,990,000.00. The disclosure for this purchase can be found here.
Surface Oncology Company Profile
Surface Oncology, Inc, a clinical-stage immuno-oncology company, engages in the development of cancer therapies. The company’s lead product candidate is the SRF231 that is in Phase I clinical trial targeting protein called cluster of differentiation (CD) 47. It is also developing SRF373 inhibiting CD73; SRF617 inhibiting CD39; and SRF388, an antibody targeting interleukin 27.
Get a free copy of the Zacks research report on Surface Oncology (SURF)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Surface Oncology Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Surface Oncology and related companies with MarketBeat.com’s FREE daily email newsletter.